Turn Therapeutics Inc.

NASDAQ:TTRX

Biotechnology

Healthcare
$8.89 -2.79%

-$0.17 today

Market cap
$271.79M
Beta
2.77
P/E (TTM)
-45.0
EPS (TTM)
-$0.13
52W Low $2.57High $26.50

Volume 0.05M

Average 0.04M

TTRX Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Turn Therapeutics Inc.NASDAQ: TTRX

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income of -$970.97K in Q1 FY2026

Q1 FY2026 net income was -$970.97K. Trailing-twelve-month net income was -$3.84M.

Context

  • Net income grew in size in 1 of the last 2 fiscal years.
  • FY2025 was the largest annual figure in the 3 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 1 analysts of -$1.37M (-57.0%) for the fiscal year ending Dec 2026, a slowdown from the +80.6% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$970.97K-447.9% QoQ
Last fiscal yearDec 2025
-$3.19M+80.6% YoY
LTMMar 2026
-$3.84M— YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter—-52.5%—
1 year+80.6%-57.0%-137.6 pp
3-year CAGR—-9.9%—
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(3.19M) USD
Year-over-year change
-80.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How TTRX compares with its peers on the latest reported figures

  • TTRX's LTM Mar 2026 net income of $3.84M is the smallest of the 9 companies compared; the peer median is $26.34M.
TTRX Competitors Peer median
Net Income for TTRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IRDOpus Genetics, Inc.LTM Mar 2026$106.93M +82.4%—892.4%
SEERSeer, Inc.LTM Mar 2026$70.49M -17.9%-7.5%468.7%
AGENAgenus Inc.LTM Mar 2026$62.51M +132.2%+0.2%50.5%
IKTInhibikase Therapeutics, Inc.LTM Mar 2026$50.96M +39.4%+38.8%—
HURATuHURA Biosciences, Inc.LTM Mar 2026$30.92M —+47.5%—
GLSIGreenwich LifeSciences, Inc.LTM Mar 2026$21.76M +31.3%+35.2%—
CGTXCognition Therapeutics, Inc.LTM Mar 2026$19.58M -41.2%+3.2%—
ANIXAnixa Biosciences, Inc.LTM Apr 2026$10.1M -17.6%-7.1%—
TTRXTurn Therapeutics Inc.LTM Mar 2026$3.84M ———
Peer median (excluding TTRX) $26.34M+31.3%+3.2%468.7%

Competitors are the stored peer set for TTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(2.29M)(1.77M)(3.19M)
Depreciation & Amortization43.92K47.48K52.75K
Deferred Income Tax000
Stock-Based Compensation640.26K352.83K419.25K
Change in Working Capital229.74K(1.86K)2.37M
Accounts Receivables000
Inventory000
Accounts Payables002.26M
Other Working Capital229.74K(1.86K)105.03K
Other Non-Cash Items6628.65K(2.21M)
Operating Cash Flow(1.38M)(1.36M)(2.56M)
Capital Expenditures(44.31K)(99.48K)(152.99K)
Acquisitions (Net)000
Purchases of Investments000
Sales of Investments000
Other Investing Activities00(152.99K)
Investing Cash Flow(44.31K)(99.48K)(152.99K)
Debt Repayment000
Common Stock Issued500K1.15M6.92M
Common Stock Repurchased000
Dividends Paid000
Other Financing Activities000
Financing Cash Flow500K1.15M6.92M
Effect of Forex Changes000
Net Change in Cash(921.99K)(308.4K)4.2M
Free Cash Flow(1.42M)(1.46M)(2.72M)

Turn Therapeutics Inc.

NASDAQ:TTRX

Intrinsic Alpha fair value

Locked

Current Price

$8.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.